These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 21350363)
1. Cancer in resource-limited settings. Krown SE J Acquir Immune Defic Syndr; 2011 Apr; 56(4):297-9. PubMed ID: 21350363 [No Abstract] [Full Text] [Related]
2. Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment. Bateganya MH; Stanaway J; Brentlinger PE; Magaret AS; Wald A; Orem J; Casper C J Acquir Immune Defic Syndr; 2011 Apr; 56(4):312-9. PubMed ID: 21350364 [TBL] [Abstract][Full Text] [Related]
3. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. Tirelli U; Spina M; Gaidano G; Vaccher E; Franceschi S; Carbone A AIDS; 2000 Aug; 14(12):1675-88. PubMed ID: 10985303 [No Abstract] [Full Text] [Related]
4. Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. Ribera JM; Navarro JT; Oriol A; López-Guillermo A; Sureda A; Abella E; Hernández-Rivas JA; Xicoy B; Grau J; Batlle M; Feliu E AIDS; 2002 Sep; 16(14):1973-6. PubMed ID: 12351963 [No Abstract] [Full Text] [Related]
5. Immune reconstitution inflammatory syndrome versus non-immune reconstitution inflammatory syndrome lymphoma in HIV patients on antiretroviral therapy. Choe PG; Park J; Park WB; Kim TM; Song KH; Bang JH; Kim ES; Park SW; Kim HB; Kim NJ; Oh MD; Choe KW Int J STD AIDS; 2016 Oct; 27(11):1013-5. PubMed ID: 26826158 [TBL] [Abstract][Full Text] [Related]
6. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection. Spina M; Carbone A; Vaccher E; Gloghini A; Talamini R; Cinelli R; Martellotta F; Tirelli U Clin Infect Dis; 2004 Jan; 38(1):142-4. PubMed ID: 14679461 [TBL] [Abstract][Full Text] [Related]
7. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Hleyhel M; Belot A; Bouvier AM; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Spano JP; Costagliola D; Grabar S; Int J Cancer; 2015 Nov; 137(10):2443-53. PubMed ID: 25976897 [TBL] [Abstract][Full Text] [Related]
8. Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Carrieri MP; Pradier C; Piselli P; Piche M; Rosenthal E; Heudier P; Durant J; Serraino D Int J Cancer; 2003 Jan; 103(1):142-4. PubMed ID: 12455069 [No Abstract] [Full Text] [Related]
9. [HIV treatment by ARV in resource-poor francophone countries]. Lepère P; Milleliri JM Med Sante Trop; 2015; 25(3):237-44. PubMed ID: 26446740 [TBL] [Abstract][Full Text] [Related]
10. Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan. Yang CJ; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC J Microbiol Immunol Infect; 2010 Aug; 43(4):278-84. PubMed ID: 20688287 [TBL] [Abstract][Full Text] [Related]
11. Does ARV therapy reduce incidence of non-Hodgkin lymphoma? Hull AE HIV Clin; 2009; 21(4):6-8. PubMed ID: 20034129 [No Abstract] [Full Text] [Related]
12. Epidemiology of HIV-associated malignancies. Dal Maso L; Serraino D; Franceschi S Cancer Treat Res; 2001; 104():1-18. PubMed ID: 11191124 [No Abstract] [Full Text] [Related]
13. Impact of HAART on HIV-linked malignancies. Laurence J AIDS Read; 2003 May; 13(5):202, 205. PubMed ID: 12800820 [No Abstract] [Full Text] [Related]
14. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. Ledergerber B; Telenti A; Egger M BMJ; 1999 Jul; 319(7201):23-4. PubMed ID: 10390454 [No Abstract] [Full Text] [Related]
15. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. Tuboi SH; Brinkhof MW; Egger M; Stone RA; Braitstein P; Nash D; Sprinz E; Dabis F; Harrison LH; Schechter M J Acquir Immune Defic Syndr; 2007 May; 45(1):52-9. PubMed ID: 17460471 [TBL] [Abstract][Full Text] [Related]
16. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. Katabira ET; Oelrichs RB AIDS; 2007 Jul; 21 Suppl 4():S5-10. PubMed ID: 17620753 [No Abstract] [Full Text] [Related]
18. Antiretroviral treatment in resource-poor settings: clinical research priorities. Rabkin M; El-Sadr W; Katzenstein DA; Mukherjee J; Masur H; Mugyenyi P; Munderi P; Darbyshire J Lancet; 2002 Nov; 360(9344):1503-5. PubMed ID: 12433534 [No Abstract] [Full Text] [Related]
19. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S; AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233 [TBL] [Abstract][Full Text] [Related]
20. Mouse viruses and human disease. Stewart AF; Cameron DW Lancet Infect Dis; 2011 Apr; 11(4):264-5. PubMed ID: 21453869 [No Abstract] [Full Text] [Related] [Next] [New Search]